{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:19Z","timestamp":1791994579744,"version":"4.4.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid efficacy and allowing significant improvements or complete remission as add-on therapy in first-line treatment-resistant patients. Herein, we report the largest retrospective study to evaluate OMZ effectiveness in patients with subepidermal autoimmune blistering diseases. Our series included 13 patients from a single center with bullous pemphigoid or mucous membrane pemphigoid, of whom 7 had mucous membrane involvement. OMZ was added to the unchanged immunosuppressive therapies. Detailed clinical and immunological data during the first year were collected, notably for specific anti-BP180-NC16A IgE and IgG, and the median total follow-up was 30 months (range: 3\u201381). Our series demonstrated that OMZ induced a significant improvement in pruritus, urticarial score, and daily blister count on day 15, allowing disease control to be achieved in a 1-month median time and complete remission (CR) in a 3-month median time in 85% of these patients previously in therapeutic impasse. At the end of the follow-up, 31% of patients achieved CR on minimal therapy after OMZ weaning without relapses, and 54% achieved CR on OMZ continuation with a minimal dose of concomitant treatment. Two patients experienced therapeutic failure (15%). At baseline, clinical variables reflecting activity were significantly positively correlated with eosinophil blood count, total IgE serum level, specific anti-BP180 IgE and IgG. While baseline anti-BP180 IgG and specific anti-BP180 IgE were significantly positively correlated, only the two patients who experienced a therapeutic failure with OMZ did not fit with this correlation, demonstrating elevated levels of anti-BP180 IgG with no measurable BP180-specific IgE. Follow-up of immunological variables demonstrated a rapid decrease of eosinophilia towards normalization, whereas a slower decline towards negativation was observed over 1 year for anti-BP180 IgG and anti BP180 IgE in patients who responded to OMZ. This case series demonstrated that OMZ is a rapidly effective biologic therapy for refractory bullous pemphigoid and mucous membrane pemphigoid, permitting rapid disease control and reduction of concomitant therapeutics.<\/jats:p>","DOI":"10.3389\/fimmu.2022.874108","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T03:11:16Z","timestamp":1650424276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Marina","family":"Alexandre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9r\u00f4me","family":"Bohelay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Le Roux-Villet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Soued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grootenboer-Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Prost-Squarcioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid Diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted Therapies for Autoimmune Bullous Diseases: Current Status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE Autoantibodies and Their Association With the Disease Activity and Phenotype in Bullous Pemphigoid: A Systematic Review","volume":"310","author":"Saniklidou","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02331","article-title":"The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid","volume":"10","author":"Messingham","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10481.x","article-title":"Detection of Linear IgE Deposits in Bullous Pemphigoid and Mucous Membrane Pemphigoid: A Useful Clue for Diagnosis","volume":"165","author":"Yayli","year":"2011","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03661.x","article-title":"IgG, IgA and IgE Autoantibodies Against the Ectodomain of BP180 in Patients With Bullous and Cicatricial Pemphigoid and Linear IgA Bullous Dermatosis","volume":"143","author":"Christophoridis","year":"2000","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.rmed.2018.06.021","article-title":"Real-World Safety and Efficacy of Omalizumab in Patients With Severe Allergic Asthma: A Long-Term Post-Marketing Study in Japan","volume":"141","author":"Adachi","year":"2018","journal-title":"Respir Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000912","article-title":"Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"27","author":"Jia","year":"2020","journal-title":"Am J Therap"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/thno.18304","article-title":"Clinical Efficacy of Omalizumab in Chronic Spontaneous Urticaria Is Associated With a Reduction of Fc\u03f5ri-Positive Cells in the Skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in Autoimmunity: Successful Treatment of Bullous Pemphigoid With Omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful Management of Severe Infant Bullous Pemphigoid With Omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful Treatment of Bullous Pemphigoid With Omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2013.130642","article-title":"Anti-IgE Monoclonal Antibody (Omalizumab) Is Effective in Treating Bullous Pemphigoid and Its Effects on Soluble CD200","volume":"60","author":"Yalcin","year":"2014","journal-title":"Clin Lab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab Therapy for Bullous Pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13758","article-title":"Successful Treatment of Bullous Pemphigoid With Omalizumab as Corticosteroid-Sparing Agent: Report of Two Cases and Review of Literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.183628","article-title":"Bullous Pemphigoid Successfully Treated with Omalizumab","volume":"82","author":"G\u00f6n\u00fcl","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000452828","article-title":"Successful Treatment of a Bullous Pemphigoid Patient With Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments","volume":"9","author":"Bilgi\u00e7 Temel","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4274\/turkderm.65983","article-title":"[Our Clinical Experience With the Use of Omalizumab in the Treatment of Bullous Pemphigoid]","volume":"51","author":"\u0130ncel Uysal","year":"2017","journal-title":"Turkderm-Turk Arch Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2845","article-title":"Biological and Clinical Response to Omalizumab in a Patient With Bullous Pemphigoid","volume":"98","author":"Menzinger","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"B20","article-title":"Successful Omalizumab Therapy for Bullous Pemphigoid Despite Transient Reaction","volume":"18","author":"Ewy","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE Blockade in Autoimmunity: Omalizumab Induced Remission of Bullous Pemphigoid","volume":"198","author":"James","year":"2019","journal-title":"Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3499","article-title":"Dramatic Exacerbation of Bullous Pemphigoid Following Rituximab and Successful Treatment With Omalizumab","volume":"29","author":"Maglie","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of Omalizumab on Fc\u03f5ri and IgE Expression in Lesional Skin of Bullous Pemphigoid","volume":"10","author":"Seyed Jafari","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12829","article-title":"Omalizumab as an Alternative Therapeutic Tool in the Treatment of Bullous Pemphigoid: A Case Report","volume":"32","author":"Vico-Alonso","year":"2019","journal-title":"Dermatol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14160","article-title":"Dipeptidyl-Peptidase IV Inhibitor-Associated Bullous Pemphigoid Efficiently Treated With Omalizumab","volume":"33","author":"Garrido","year":"2020","journal-title":"Dermatol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing Evidence for Omalizumab in the Treatment of Bullous Pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1136\/ejhpharm-2020-002418","article-title":"Dramatic Improvement of Bullous Pemphigoid With Omalizumab in an Elderly Patient","volume":"2020","author":"Navarro-Trivi\u00f1o","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_438_19","article-title":"Complete Remission in a Patient With Treatment Refractory Bullous Pemphigoid After a Single Dose of Omalizumab","volume":"11","author":"Sinha","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17229","article-title":"Omalizumab: An Underutilized Treatment Option in Bullous Pemphigoid Patients With Co-Morbidities","volume":"35","author":"De","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2020.09.577","article-title":"Onset of Acquired Haemophilia A After Omalizumab Treatment in Severe Bullous Pemphigoid \u2013 a Report on Two Cases Successfully Treated With Mycophenolate Mofetil","volume":"148","author":"Mangin","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2020.08.053","article-title":"Refractory Bullous Pemphigoid With IgE Anti-BP230 and IgG Anti-P200 Antibodies Successfully Treated With Omalizumab","volume":"148","author":"Sarrazin","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid","volume":"11","author":"Seyed Jafari","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01030","article-title":"Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients","volume":"9","author":"Gaudin","year":"2018","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09566.x","article-title":"Place of Human Amniotic Membrane Immunoblotting in the Diagnosis of Autoimmune Bullous Dermatoses","volume":"162","author":"Grootenboer-Mignot","year":"2010","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.9.1075","article-title":"Evaluation of Clinical Criteria for Diagnosis of Bullous Pemphigoid. French Bullous Study Group","volume":"134","author":"Vaillant","year":"1998","journal-title":"Arch Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.370","article-title":"The First International Consensus on Mucous Membrane Pemphigoid: Definition, Diagnostic Criteria, Pathogenic Factors, Medical Treatment, and Prognostic Indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and Outcome Measures for Bullous Pemphigoid: Recommendations by an International Panel of Experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and Outcome Measures for Mucous Membrane Pemphigoid: Recommendations of an International Panel of Experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE Autoantibodies to BP180 and BP230 and Their Relationship to Clinical Features in Bullous Pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and Mortality of Bullous Pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19611","article-title":"International Validation of the Bullous Pemphigoid Disease Area Index Severity Score and Calculation of Cut-Off Values for Defining Mild, Moderate and Severe Types of Bullous Pemphigoid","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"adv00320","DOI":"10.2340\/00015555-3683","article-title":"Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study","volume":"100","author":"Briand","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12040","article-title":"A Retrospective Review of the Therapeutic Response With Remission in Patients With Newly Diagnosed Bullous Pemphigoid","volume":"55","author":"Chuah","year":"2014","journal-title":"Australas J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.056","article-title":"Biologic Treatment Outcomes in Mucous Membrane Pemphigoid: A Systematic Review","author":"Lytvyn","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.08.005","article-title":"Updated French Guidelines for the Therapeutic Management of Bullous Pemphigoid","author":"Castel","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13717","article-title":"Management of Bullous Pemphigoid: The European Dermatology Forum Consensus in Collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17395","article-title":"European Guidelines (S3) on Diagnosis and Management of Mucous Membrane Pemphigoid, Initiated By the European Academy of Dermatology and Venereology \u2013 Part II","volume":"35","author":"Schmidt","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/07853890.2020.1742367","article-title":"Factors Associated With the Activity and Severity of Bullous Pemphigoid: A Review","volume":"52","author":"Liu","year":"2020","journal-title":"Ann Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1038\/s41598-019-40203-7","article-title":"B-Cell Depletion Induces a Shift in Self Antigen Specific B-Cell Repertoire and Cytokine Pattern in Patients With Bullous Pemphigoid","volume":"9","author":"Berkani","year":"2019","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk Factors for Relapse in Patients With Bullous Pemphigoid in Clinical Remission: A Multicenter, Prospective, Cohort Study","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.874108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T03:11:19Z","timestamp":1650424279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.874108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2022.874108"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.874108","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"article-number":"874108"}}